Ovarian cancer

There are 437 papers on ovarian cancer in aging research: 15 trials and 193 observational studies in people, 24 in animals, 15 in cells, 139 reviews.

Disease

437 papers study it206 more mention it144 findings

44 new papers in 30 daysSee all 643 papers on ovarian cancer

At a glance

Advanced age increases ovarian cancer formation and volume in a rat study, and cellular senescence promotes ovarian cancer in a human-cell study. Human studies link later menopause and pathogenic BRCA1 or BRCA2 variants with higher ovarian cancer risk, while telomere-length associations point both ways.

144 findings in 101 papers from 2007 to 2026, 36 of them since April 2026

“later menopause (at age ≥55 years; HR, 1.36 [95% CI, 1.11-1.66]), longer reproductive span (≥40 years; HR, 1.21 [95% CI, 1.09-1.34]),”
Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or OlderJAMA network open2026doi:10.1001/jamanetworkopen.2025.56840
  • Human trial15
  • Humans193
  • Animals24
  • Cells15
  • In silico43

Interventions

8

Lactation

no changein humans1HR 0.94

1 study
  1. Lactation was not clearly linked with ovarian cancer in humans (HR 0.94, 95% CI: 0.82-1.09).

    “ovarian (0.94 [0.82-1.09] per month)”

    Humansfemalesn = 6,880

    Associations Between Duration of Lactation and Maternal Risk of Obesity-Related Cancers-A Historical Birth Cohort Study

    Maternal & child nutrition

More on Lactation

Hedgehog signaling inhibitors

downin mice1

1 study
  1. Hedgehog signaling inhibitors decrease ovarian cancer in aged mice bearing ovarian cancer.

    “Pharmacologic Hedgehog inhibition in aged mice suppressed tumor growth, reduced metastasis”

    Animalsin aged mice bearing ovarian cancerfemales

    Ovarian cancer grew and spread more in older mice

    bioRxiv : the preprint server for biologyPreprint

More on Hedgehog signaling inhibitors

Salpingectomy

downin humans1

1 study
  1. Salpingectomy prevents ovarian cancer in humans during indicated benign surgery.

    “Opportunistic salpingectomy during indicated benign surgery is supported as an ovarian cancer prevention strategy that preserves ovarian hormonal function”

    Reviewduring indicated benign surgery

    Complex benign gynecology in perimenopause: current evidence and future directions

    Current opinion in obstetrics & gynecology

More on Salpingectomy

Aspirin

downin humans1

1 study
  1. Aspirin protects against ovarian cancer in humans.

    “Long-term aspirin usage had a moderate protective effect against ovarian cancer”

    Reviewlong-term

    Aspirin's Dual Role in Cancer: A Systematic Review of the Current Evidence

    International Journal of Drug Delivery Technology

More on Aspirin

Prophylactic salpingo-oophorectomy

downin humans1

1 study
  1. Prophylactic salpingo-oophorectomy is linked with lower ovarian cancer in humans (incidental findings in BRCA1 and BRCA2 carriers after PBSO) (2.0% (6 of 293) incidental ovarian cancer or STIC; 1.7% gBRCA1, 0.3% gBRCA2).

    “with 6 women having an incidental finding of ovarian cancer and STIC respectively (=2.0%; 1.7% gBRCA1 and 0.3% gBRCA2)”

    Humansincidental findings in BRCA1 and BRCA2 carriers after PBSOovaryfemalesn = 293

    Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomy in BRCA1/2 Germline Variant Carriers: A Retrospective Cohort Study From a Single German Center

    Cancer medicine

More on Prophylactic salpingo-oophorectomy

Coffee

no changein humans1

1 study
  1. Coffee showed no clear effect on ovarian cancer in humans.

    “However, no statistical association was found between coffee and ovarian cancer.”

    Review

    COFFEE CONSUMPTION AND FEMALE CANCERS: A NARRATIVE REVIEW OF RECENT EVIDENCE

    EuroMediterranean Biomedical Journal

More on Coffee

Risk-reducing salpingo-oophorectomy

downin humans1

1 study
  1. Risk-reducing salpingo-oophorectomy prevents ovarian cancer in women at increased risk.

    “Women at increased risk can choose to have an operation to remove the fallopian tubes and ovaries, which is the most effective way to prevent ovarian cancer.”

    Reviewin women at increased riskfemales

    Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66

    BJOG : an international journal of obstetrics and gynaecology

More on Risk-reducing salpingo-oophorectomy

Risk-reducing bilateral salpingo-oophorectomy

downin humans1

1 study
  1. Risk-reducing bilateral salpingo-oophorectomy prevents ovarian cancer in humans (Carriers of pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D).

    “We found that the benefit of RRSO is well-established for pathogenic variants in BRCA1/2 as well as BRIP1 and RAD51C/D”

    ReviewCarriers of pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D

    Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes

    JCO oncology practice

More on Risk-reducing bilateral salpingo-oophorectomy

Effects

3

CD44

upin silico1

1 study
  1. Ovarian cancer increases CD44 in silico (ovarian cancer and aging).

    “TREM1, SERPINB2, and CD44 were upregulated, while DST was downregulated”

    In silicoovarian cancer and aging

    Integrative Analysis Reveals Genes Causal Relation with Ovarian Cancer and aging

    Current topics in medicinal chemistry

More on CD44

UCP2

upin silico1

1 study
  1. Ovarian cancer increases UCP2 in ovarian cancer.

    “PRKCD and UCP2 were significantly upregulated in ovarian cancer.”

    In silicoin ovarian cancer

    Molecular characteristics of early- and late-onset ovarian cancer: insights from multidimensional evidence

    Journal of ovarian research

More on UCP2

PRKCD

upin silico1

1 study
  1. Ovarian cancer increases PRKCD in ovarian cancer.

    “PRKCD and UCP2 were significantly upregulated in ovarian cancer.”

    In silicoin ovarian cancer

    Molecular characteristics of early- and late-onset ovarian cancer: insights from multidimensional evidence

    Journal of ovarian research

More on PRKCD

Upstream

11

Hypertension

no changein humans1RR 1.06

1 study
  1. Hypertension showed no clear effect on ovarian cancer in humans (RR 1.06, 95% CI 0.96-1.20).

    “There was a risk ratio (RR) of 1.06 (95% CI, 0.96-1.20) for ovarian cancer in patients with hypertension”

    Review

    Hypertension as a Predictor of Ovarian Cancer Risk: A Systematic Review and Meta-Analysis

    Health science reports

More on Hypertension

Age at menarche

no changein humans1

1 study
  1. Age at menarche was not clearly linked with ovarian cancer in humans (age at menarche).

    “whereas age at menarche showed no association with ovarian cancer.”

    Humansage at menarchefemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Mismatch repair genes

no changein humans1

1 study
  1. mismatch repair genes showed no clear effect on ovarian cancer in humans.

    “Ovarian cancer risk did not differ significantly by gene.”

    Reviewfemales

    Gene-specific cancer risks in female Lynch syndrome carriers: A copula-based meta-analysis

    Maturitas

PRKCD

upin silico1

1 study
  1. PRKCD increases ovarian cancer in ovarian cancer.

    “PRKCD facilitates epithelial-mesenchymal transition (EMT), contributing to ovarian cancer progression”

    In silicoin ovarian cancer

    Molecular characteristics of early- and late-onset ovarian cancer: insights from multidimensional evidence

    Journal of ovarian research

More on PRKCD

Advanced age

upin rats1

1 study
  1. Advanced age increases ovarian cancer in rats (p = 0.047 for formation, p = 0.002 for volume).

    “The rates of tumor formation (p = 0.047) and tumor volume (p = 0.002) were significantly higher in the aged rats than in their young counterparts.”

    Animals

    Regulation of Age-Related Lipid Metabolism in Ovarian Cancer

    International journal of molecular sciences

Weight-adjusted-waist index

no changein humans1OR 1.16

1 study
  1. Weight-adjusted-waist index was not clearly linked with ovarian cancer in humans (OR = 1.16, 95% CI: 0.48-2.72, p = 0.5359).

    “No significant association was found between WWI and the risk of ovarian cancer (OR = 1.16, 95% CI: 0.48-2.72, p = 0.5359).”

    Humansfemalesn = 4,144

    Association between weight-adjusted-waist index and gynecologic cancers: a population-based study

    Frontiers in nutrition

More on Weight-adjusted-waist index

Body mass index

no changein humans1OR 0.97

1 study
  1. Body mass index was not clearly linked with ovarian cancer in humans (without endometriosis) (OR 0.97, 95% CI 0.91–1.05).

    “not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05)”

    Humanswithout endometriosisBMI 25-<30 kg/m2 versus BMI 18.5-<25 kg/m2females

    Effects of risk factors for ovarian cancer in women with and without endometriosis

    Fertility and sterility

Progesterone

no changein humans1HR 1.16

1 study
  1. Progesterone was not clearly linked with ovarian cancer in humans (postmenopausal women) (HR 1.16, 95% CI 0.58-2.33).

    “Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85-4.11); P trend = 0.17] or ovarian cancer risk [1.16 (0.58-2.33); 0.73].”

    Humanspostmenopausal womenserum12 follow-up yearsfemales

    Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B∼FIT Cohort

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on Progesterone

LDL cholesterol

no changein humans1

1 study
  1. LDL cholesterol was not clearly linked with ovarian cancer in humans.

    “Overall, no clear patterns were observed for HDL-C, LDL-C, or triglycerides and ovarian cancer risk.”

    Humans

    Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on LDL cholesterol

HDL cholesterol

no changein humans1

1 study
  1. HDL cholesterol was not clearly linked with ovarian cancer in humans.

    “Overall, no clear patterns were observed for HDL-C, LDL-C, or triglycerides and ovarian cancer risk.”

    Humans

    Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

More on HDL cholesterol

All 11

Associations

94

Oral contraceptives

downin humans6HR 0.57–0.75

6 studies
  1. Oral contraceptives are linked with a lower risk of ovarian cancer in humans (BRCA2 carriers) (HR 0.57, 95% CI 0.35-0.94).

    “Oral contraceptive use was associated with a decrease in the risk of ovarian cancer in BRCA2 carriers (HR = 0.57, 95% CI 0.35-0.94, p = 0.028)”

    HumansBRCA2 carriersfemalesn = 687

    Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant

    Breast cancer (Tokyo, Japan)

  2. Oral contraceptives are linked with a lower risk of ovarian cancer in humans.

    “oral contraceptive use for ≥1 year were also associated with reduced risk.”

    Humans≥1 yearfemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  3. Oral contraceptives are associated with ovarian cancer in humans (Premenopausal women) (HR 0.75, 95% CI 0.61–0.93).

    “Breastfeeding for 12 months or longer and oral contraceptive use for 1 year or longer were associated with lower risk in premenopausal women”

    HumansPremenopausal womenoral1 year or longerfemalesn = 932,637

    Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older

    JAMA network open

  4. Oral contraceptives are associated with ovarian cancer in humans (vs. controls without cancer) (p < 0.001).

    “whereas full-term pregnancy (p 0.001), breastfeeding (p 0.001), and oral contraceptive use (p 0.001) were less frequent.”

    Humansvs. controls without cancerfemales

    Predictive informativeness of risk factors for the development of ovarian cancer of different histological types: a randomized study

    Kazan medical journal

  5. Oral contraceptives are linked with a lower risk of ovarian cancer in humans (P = 0.79 for trend).

    “However, we observed no such attenuation in the oral contraceptive-associated risk reductions (P = 0.79 for trend in HR with increasing age).”

    Humansfemalesn = 310,290

    Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

  6. Oral contraceptives are associated with ovarian cancer in humans (Current or recent use).

    “and a lower risk of colorectal and ovarian cancer.”

    ReviewCurrent or recent usefemales

    Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study

    American journal of public health

More on Oral contraceptives

Parity

downin humans5HR 0.68

5 studies
  1. Parity is linked with a lower risk of ovarian cancer in humans (compared with nulliparity).

    “Compared with nulliparity, having ≥2 births was associated with lower risk.”

    Humanscompared with nulliparityfemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  2. Parity is associated with ovarian cancer in humans (Premenopausal women) (HR 0.68, 95% CI 0.58–0.79).

    “Parity of 2 or more births was associated with lower risk in both groups”

    HumansPremenopausal women2 or more birthsfemalesn = 932,637

    Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older

    JAMA network open

  3. Parity is linked with a lower risk of ovarian cancer in humans (RR = 1.43 among women who had never given birth).

    “Subgroup analysis showed that parity may significantly reduce the ovarian cancer risk, which was higher among women who had never given birth (RR = 1.43, p < 0.0025)”

    Humansovaryfemales

    Hypertension and ovarian cancer risk: a meta-analysis of observational studies

    Archives of medical science : AMS

  4. Parity is associated with ovarian cancer in humans (married postmenopausal women) (13.2% lower incidence per additional child (95% CI 11.2–15.3%)).

    “ovarian cancer 13.2% (11.2-15.3) and endometrial cancer 10.9% (8.9-12.8) with similar curvilinear relationship.”

    Humansmarried postmenopausal womeneach additional child1960–2005femalesn = 385,816

    The curvilinear relationships between grand parity and incidence of hormone-dependent cancers; follow-up of postmenopausal women in the Norwegian 1960 Census

    medRxivPreprint

  5. Parity lowers the risk of ovarian cancer in humans.

    “parity reduces the risk of OC”

    Review

    Oxidative Stress, Parity History, and Remnant Follicles in the Aged Ovary: Insights on Ovarian Cancer Risk and Protection

    Antioxidants (Basel, Switzerland)

More on Parity

Hormone replacement therapy

upin humans4upin reviews1HR 1.2

5 studies
  1. Hormone replacement therapy is linked with a higher risk of ovarian cancer in humans.

    “Menopausal hormone replacement therapy use for ≥5 years was also associated with higher risk”

    Humans≥5 yearsfemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  2. Hormone replacement therapy is associated with ovarian cancer in humans (Postmenopausal women) (HR 1.20, 95% CI 1.07–1.34).

    “hormone replacement therapy use for 2 to 5 years (HR, 1.20 [95% CI, 1.07-1.34]) were associated with higher risk.”

    HumansPostmenopausal women2 to 5 yearsfemalesn = 1,353,137

    Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older

    JAMA network open

  3. Hormone replacement therapy is associated with ovarian cancer in humans (vs. controls without cancer) (45.0% vs. 33.6%, p = 0.003).

    “The main group more frequently reported the use of postmenopausal hormone replacement therapy (45.0% vs. 33.6%; p = 0.003)”

    Humansvs. controls without cancerfemales

    Predictive informativeness of risk factors for the development of ovarian cancer of different histological types: a randomized study

    Kazan medical journal

  4. Hormone replacement therapy is associated with ovarian cancer in humans (White women) (OR 1.38, 95% CI 1.22–1.57).

    “Long-term MHT use, ≥10 years, was associated with an increased ovarian cancer risk for White women (OR = 1.38, 95%CI: 1.22-1.57)”

    HumansWhite women≥10 yearsfemales

    Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium

    British journal of cancer

  5. Hormone replacement therapy raises the risk of ovarian cancer.

    “The major risk factors for ovarian cancer include older age, genetics, family history, hormone replacement therapy, nulliparity, and dietary fat.”

    Review

    Epidemiology and risk factors for ovarian cancer

    Przeglad menopauzalny = Menopause review

More on Hormone replacement therapy

Telomere length

upin humans2downin humans1upin silico1OR 0.67–1.273

4 studies
  1. Telomere length is linked with a higher risk of ovarian cancer in humans (OR 1.273, 95 % CI 1.012-1.602).

    “The IVW method supported TL as a risk factor for malignant (OR = 1.273, 95 % CI = 1.012-1.602)”

    Humans

    Causal effects of telomere length on ovarian tumor risk: Insights from genetic evidence

    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

  2. Telomere length is linked with a higher risk of ovarian cancer in humans (OR 1.27, 95% CI 1.01-1.60).

    “telomere length and OC (IVW; OR = 1.27, 95%CI: 1.01-1.60, P = .04)”

    Humans

    Causal association between telomere length and female cancers: a two-sample Mendelian randomization study

    Postgraduate medical journal

  3. Telomere length is linked with a lower risk of ovarian cancer in humans (OR 0.67, 95% CI 0.46-0.97).

    “women in the top quartile of LTL had an OR for ovarian cancer of 0.67 (95% CI, 0.46-0.97) compared with those in the bottom quartile.”

    Humansleukocyte

    Prediagnosis Leukocyte Telomere Length and Risk of Ovarian Cancer

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

  4. Telomere length raises the risk of ovarian cancer in silico (OR = 1.27, 95% CI: 1.01-1.60).

    “telomere length positively associated with increased risk (OR = 1.27, 95% CI: 1.01-1.60, P = 3.90 × 10−2)”

    In silico

    Molecular characteristics of early- and late-onset ovarian cancer: insights from multidimensional evidence

    Journal of ovarian research

More on Telomere length

Breastfeeding

downin humans3HR 0.86

3 studies
  1. Breastfeeding is linked with a lower risk of ovarian cancer in humans.

    “Breastfeeding for ≥12 months and oral contraceptive use for ≥1 year were also associated with reduced risk.”

    Humans≥12 monthsfemales

    Reproductive history, hormonal exposure, and ovarian cancer risk in post-menopausal women: evidence from a nationwide Korean cohort

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  2. Breastfeeding is associated with ovarian cancer in humans (Premenopausal women) (HR 0.86, 95% CI 0.77–0.96).

    “Breastfeeding for 12 months or longer and oral contraceptive use for 1 year or longer were associated with lower risk in premenopausal women”

    HumansPremenopausal women12 months or longerfemalesn = 932,637

    Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older

    JAMA network open

  3. Breastfeeding lowers the risk of ovarian cancer in humans (premenopausal women) (HR 0.86, 95% CI 0.77–0.96).

    “Kim JH et al., reported a significant risk reduction among premenopausal women (hazard ratio 0.86, 95% confidence interval 0.77–0.96)”

    Reviewpremenopausal women≥12 months

    Impact of Breastfeeding duration on the Risk of Ovarian Cancer: Systematic Review

    Saudi Journal of Medical and Pharmaceutical Sciences

More on Breastfeeding

Endometriosis

upin humans2HR 2.04

2 studies
  1. Endometriosis is associated with ovarian cancer in humans (Surgically diagnosed endometriosis versus no endometriosis; adjusted analysis) (HR 2.04, 95% CI 1.83–2.27).

    “After adjustment, the hazard of ovarian cancer in individuals with endometriosis vs. those without was 2.04 (95% CI 1.83-2.27 p<0.0001).”

    HumansSurgically diagnosed endometriosis versus no endometriosis; adjusted analysis

    Are Patients with Endometriosis at an Increased Risk for Gynecologic Malignancy?

    Journal of minimally invasive gynecology

  2. Endometriosis is associated with ovarian cancer in humans (vs. controls without cancer) (13.4% vs. 7.5%, p = 0.02).

    “endometriosis (13.4% vs. 7.5%; p = 0.02)”

    Humansvs. controls without cancerfemales

    Predictive informativeness of risk factors for the development of ovarian cancer of different histological types: a randomized study

    Kazan medical journal

More on Endometriosis

CA125

mixedin humans1upin silico1

2 studies
  1. CA125 predicts ovarian cancer in silico.

    “Menopause status, CA125-related interactions, and neutrophil-based interactions were identified as important predictors by SHAP analysis.”

    In silico

    Clinical Weighting and Symptom Interaction-based Risk-Stratified Learning for Early Prediction of Ovarian Cancer Using Explainable Machine Learning

    Indian Journal of Science and Technology

  2. CA125 is associated with ovarian cancer in humans (early detection of ovarian cancer).

    “Integration with CA125 may improve sensitivity but can reduce specificity”

    Reviewearly detection of ovarian cancer

    DNA methylation biomarkers for early detection of ovarian cancer

    Molecular biology reports

More on CA125

BRCA2

upin humans2

2 studies
  1. BRCA2 is linked with a higher risk of ovarian cancer in humans (24.1% (95% CI, 15.1-36.6)).

    “The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier and 24.1% (95% CI, 15.1-36.6) for a BRCA2 carrier.”

    Humansfemales

    Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers

    JAMA surgery

  2. BRCA2 is linked with a higher risk of ovarian cancer in humans (pathogenic variant carriers) (29.3% (95% CI, 14.2%-41.7%)).

    “and 29.3% (95% CI, 14.2%-41.7%) for BRCA2 pathogenic variant carriers, compared with 1.5% (95% CI, 1.3%-1.7%) in the general population.”

    Humanspathogenic variant carriersovaryfemales

    Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing

    JAMA network open

More on BRCA2

BRCA1

upin humans2

2 studies
  1. BRCA1 is linked with a higher risk of ovarian cancer in humans (55.0% (95% CI, 48.8-61.9)).

    “The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier”

    Humansfemales

    Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers

    JAMA surgery

  2. BRCA1 is linked with a higher risk of ovarian cancer in humans (pathogenic variant carriers) (56.0% (95% CI, 40.0%-67.7%)).

    “corresponding ovarian cancer incidence was 56.0% (95% CI, 40.0%-67.7%) for BRCA1 pathogenic variant carriers and 29.3% (95% CI, 14.2%-41.7%) for BRCA2 pathogenic variant carriers”

    Humanspathogenic variant carriersovaryfemales

    Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing

    JAMA network open

More on BRCA1

PALB2

upin humans2

2 studies
  1. PALB2 is linked with a higher risk of ovarian cancer in humans (female carriers of PALB2 PGVs) (5.38% (95% CI 2.94 to 8.26) vs 1.10%).

    “cumulative lifetime risk for OC for female carriers of PALB2 PGVs at age 80 years was estimated to be 5.38% (95% CI [2.94 to 8.26])”

    Humansfemale carriers of PALB2 PGVsfemales

    Age-Specific Ovarian Cancer Risk Among Individuals With Pathogenic Variants in PALB2

    JCO precision oncology

  2. PALB2 is associated with ovarian cancer in humans (PALB2 variant carriers; risk depends on family history).

    “In PALB2, RRSO is particularly controversial as newer studies consistently demonstrate an increased risk of OC that is dependent on family history”

    ReviewPALB2 variant carriers; risk depends on family history

    Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes

    JCO oncology practice

More on PALB2

All 94

Trial sponsors

  • AstraZeneca

    Company12 trialsPhase 43,678 people

  • Roche

    Company11 trialsPhase 34,216 people

  • Merck & Co.

    Company10 trialsPhase 36,012 people

  • AbbVie

    Company9 trialsPhase 32,689 people

  • Amgen

    Company7 trialsPhase 32,470 people

  • Pfizer

    Company6 trialsPhase 31,962 people

  • Incyte

    Company5 trialsPhase 31,142 people

  • Genentech

    Company5 trialsPhase 3791 people

Funding

93 grants since 2017

National Cancer Institute$96MNational Institute on Aging$2.5MGouvernement du Canada | Canadian Institutes of Health ResearchCA$3.9M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Advanced age increases ovarian cancer formation and volume in a rat study, while cellular senescence promotes ovarian cancer in a human-cell study. Human cohorts link BRCA1/BRCA2 pathogenic variants and later menopause with higher ovarian cancer risk; telomere-length associations point both ways. Bilateral salpingo-oophorectomy at benign hysterectomy is associated with lower risk.

  2. Summary rewritten as its findings changed.

    As it read before

    A rat study reports greater ovarian tumor formation and volume with advanced age. Human studies link later menopause and BRCA1/BRCA2 pathogenic variants with higher ovarian cancer risk, and parity with lower risk. Human associations between telomere length and ovarian cancer point both ways.

  3. Summary rewritten as its findings changed.

    As it read before

    Advanced age increases ovarian tumor formation and volume in a rat study, while reviews link older age with ovarian cancer risk. Human studies associate BRCA1/2 pathogenic variants and obesity with higher risk, and parity and oral contraceptive use with lower risk. Telomere-length associations in humans point both ways.

  4. Summary rewritten as its findings changed.

    As it read before

    Ovarian tumor formation and volume increase with advanced age in a rat study. Human studies link BRCA1/2 pathogenic variants and higher body mass index with higher ovarian cancer risk, and parity and oral contraceptive use with lower risk. Telomere-length associations point both ways.

  5. Summary rewritten as its findings changed.

    As it read before

    One human study links BRCA1 and BRCA2 carrier status to increased ovarian cancer risk. A human preprint finds serum CA-125-STn predicts ovarian cancer within five years of sampling, while another human study reports no effect of lactation on ovarian cancer.

Latest

Dec 2025: 11Jan 2026: 45Feb 2026: 34Mar 2026: 36Apr 2026: 24May 2026: 12Jun 2026: 12Jul 2026: 19Aug 2026: 28Sep 2026: 28Oct 2026: 30Nov 2026: 23302 papers in 12 months

See all 643 papers on ovarian cancer